Nintedanib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-NINTEDANIB |
|---|---|
| Type | Drug |
| Aliases | OfevVargatefНінтеданіб |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | Triple angiokinase inhibitor (VEGFR1-3 / PDGFRα-β / FGFR1-3) |
|---|---|
| Mechanism | Oral multikinase inhibitor blocking VEGFR1-3, PDGFRα/β, and FGFR1-3. Anti-angiogenic mechanism complementary to docetaxel cytotoxicity. Approved in EU as Vargatef + docetaxel for 2L NSCLC adenocarcinoma per LUME-Lung 1; also approved for IPF / progressive fibrosing ILD as Ofev (separate indication). |
| Typical dosing | NSCLC (Vargatef + docetaxel): 200 mg PO BID days 2-21 of each 21-day cycle (in combination with docetaxel 75 mg/m² IV day 1). |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
LUME-Lung 1 (Reck 2014): docetaxel + nintedanib vs docetaxel in 2L NSCLC — adenocarcinoma OS benefit (12.6 vs 10.3 mo, HR 0.83); particularly active in patients progressing within 9 mo of 1L (mOS 10.9 vs 7.9 mo, HR 0.75). Squamous histology no benefit. Oral PO alternative to ramucirumab (REVEL) for fit adenocarcinoma 2L.
Used By
No reverse references found in the YAML corpus.